We have sent a letter to Senate Health, Education, Labor and Pensions (HELP) Committee leadership that highlights the implications of the Verifying Accurate Leading-edge IVCT Development (VALID) Act. Because the bill would modify the regulatory framework for laboratory developed tests, the VALID Act could have serious unintended consequences for children’s health and children’s hospitals. We are asking the committee to address those concerns before advancing the Senate FDA user fee package legislation that includes the VALID Act.
VALID Act Letter
We sent a letter to Senate HELP Committee leadership to highlight the implications of the VALID Act.
Related Content
CHA Responds to 340B Draft Bill and Request for Information
CHA Response to Cell and Gene Therapy RFI
CHA Submits Comments for Energy and Commerce Discussion Draft on Drug Shortages
CHA Responds to 340B Draft Bill and Request for Information
The 340B program supports children’s hospitals in their mission to serve low-income and underinsured children regardless of their insurance status.
April 04, 2024
CHA Response to Cell and Gene Therapy RFI
Cell and gene therapies have the potential to address unmet pediatric medical needs, reduce the need for costly chronic care, and help address health disparities.
Feb. 05, 2024
CHA Submits Comments for Energy and Commerce Discussion Draft on Drug Shortages
CHA submitted a comment letter to the Energy and Commerce Committee to highlight pediatric needs when addressing drug shortages.
Oct. 23, 2023
